How effective is aximini as a single agent? Is it outstanding?

The therapeutic effect of aceminib as a single agent is significant, especially in the treatment of chronic myeloid leukemia (CML). In a pivotal clinical trial, Aceminib demonstrated an impressive high molecular response rate. Specifically, at 24 weeks, nearly twice as many patients on aximinib achieved a major molecular response (MMR) as on other drugs, such as bosutinib. By 96 weeks, nearly 40% of patients had achieved MMR. This data was significantly higher than the control group, demonstrating the excellent efficacy of aceminib as a single-agent treatment.

A significant advantage of aceminib is its ability to overcome resistance or intolerance toTKIs. This is an important treatment breakthrough for many CML patients who have developed resistance to other TKIs. Through its unique mechanism of action, Asiminib is expected to solve the problems of TKI resistance and intolerance in future CML treatment options.

Compared with traditional chemotherapy drugs and otherTKIs, aceminib has relatively mild side effects, making it easier for patients to tolerate the treatment. Its higher targeting and lower side effects provide patients with safer and more effective treatment options. In addition, aximini has a long half-life and patients do not need to take frequent medication, which further improves the convenience of treatment and patient compliance.

Because Aceminib has mild side effects and significant efficacy, it can help patients maintain treatment, thereby reducing the discontinuation rate. This is critical forCMLpatients who require long-term treatment.